Mycophenolate Mofetil · Regulatory label update

FDA supplemental approval: Mycophenolate Mofetil (REMS)

U.S. Food and Drug Administration · July 29, 2026

Regulatory Update Why this matters to you Expert discussion

An action by a regulator. Authoritative on labelling and availability.

AI Summary

The FDA approved a supplemental application (REMS) for mycophenolate mofetil hydrochloride injectable 500 mg/vial on 29 July 2026. This is a regulatory action establishing post-marketing safety requirements; the record does not contain efficacy or clinical trial data.

What was studied

Regulatory label update.

Key findings

Supplemental REMS approval for mycophenolate mofetil hydrochloride injectable formulation (500 mg/vial) granted by FDA

Safety

This record does not contain clinical trial results, efficacy data, or comparative safety evidence. Regulatory approval of a REMS does not establish clinical benefit; consult product labeling and published evidence for efficacy and safety information.

Who this may help

The source did not state who this applies to in practice.

Plain-language summary

This is an FDA supplemental approval action establishing a Risk Evaluation and Mitigation Strategy (REMS) for mycophenolate mofetil; it reflects a regulatory requirement, not a clinical trial outcome.

Reported figures

Quoted from the source exactly as published.

Approval date2026-07-29

Product strength500 mg/vial

RouteInjectable injection

Caveats

This record does not contain clinical trial results, efficacy data, or comparative safety evidence.
The record does not specify the scope or content of the REMS requirements.
No patient population, sample size, or clinical outcomes are reported.
Regulatory approval of a REMS does not establish clinical benefit; consult product labeling and published evidence for efficacy and safety information.

Evidence assessment

Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.

Study design

insufficient

Regulatory action record; no clinical study design present.

Directness

insufficient

Record does not report clinical outcomes or efficacy data.

Consistency

insufficient

Single regulatory action; no comparative or replicated evidence provided.

Risk of bias

insufficient

Regulatory record; trial methodology and bias assessment not applicable.

Sample adequacy

insufficient

No patient population or sample size data reported in this record.

Source abstract

Drugs@FDA record for application ANDA203859. This is a regulatory action record, not a clinical study. Brand name: MYCOPHENOLATE MOFETIL. Active ingredient: MYCOPHENOLATE MOFETIL. Sponsor: MYLAN LABS LTD. Submission type: SUPPL (supplement). Submission class: REMS. Approval status date: 2026-07-29. Products: MYCOPHENOLATE MOFETIL HYDROCHLORIDE, INJECTABLE, INJECTION, MYCOPHENOLATE MOFETIL HYDROCHLORIDE 500MG/VIAL.

Follow from this

Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.

Mycophenolate MofetilMylan Labs